HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Inflammatory Breast Neoplasms

Subscribe to New Research on Inflammatory Breast Neoplasms

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

Also Known As:

Inflammatory Breast Cancer (IBC); Inflammatory Breast Carcinoma; Breast Cancer, Inflammatory; Breast Cancers, Inflammatory; Breast Carcinoma, Inflammatory; Breast Carcinomas, Inflammatory; Breast Neoplasm, Inflammatory; Breast Neoplasms, Inflammatory; Cancer, Inflammatory Breast; Cancers, Inflammatory Breast; Carcinoma, Inflammatory Breast; Carcinomas, Inflammatory Breast; Inflammatory Breast Cancers; Inflammatory Breast Carcinomas; Inflammatory Breast Neoplasm; Neoplasm, Inflammatory Breast; Neoplasms, Inflammatory Breast; Inflammatory Breast Cancer

Networked: 457 relevant articles (32 outcomes, 73 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Breast Neoplasms (Breast Cancer)
2.	Neoplasms (Cancer)
3.	Neoplasm Metastasis (Metastasis)
4.	Noninfiltrating Intraductal Carcinoma (DCIS)
5.	Carcinoma (Carcinomatosis)

Experts

1.	Cristofanilli, Massimo: 24 articles (11/2015 - 02/2004)
2.	Ueno, Naoto T: 16 articles (06/2015 - 02/2008)
3.	Woodward, Wendy A: 13 articles (12/2015 - 07/2007)
4.	Merajver, Sofia D: 11 articles (06/2010 - 01/2002)
5.	Vermeulen, Peter B: 10 articles (06/2015 - 09/2003)
6.	Hortobagyi, Gabriel N: 10 articles (01/2014 - 02/2004)
7.	van Golen, Kenneth L: 9 articles (06/2015 - 01/2002)
8.	Barsky, Sanford H: 9 articles (01/2013 - 05/2002)
9.	Dirix, Luc Y: 9 articles (10/2012 - 09/2003)
10.	Bertucci, François: 8 articles (06/2015 - 12/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Inflammatory Breast Neoplasms:

1.	lapatinib (GW572016)FDA Link 06/01/2009 - "Lapatinib monotherapy is a potentially effective treatment for relapsed or refractory HER2+ inflammatory breast cancer. " 01/01/2007 - "Lapatinib shows promise for inflammatory breast cancer." 01/01/2013 - "A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer." 06/01/2009 - "From March, 2005, to September, 2007, 126 patients with relapsed or refractory HER2+ inflammatory breast cancer were treated with lapatinib 1500 mg once daily in a non-randomised, open-label, phase II study. " 06/01/2009 - "Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study."
2.	Paclitaxel (Taxol)FDA LinkGeneric 02/01/2004 - "It may be concluded that the addition of paclitaxel to anthracycline-based therapy resulted in a statistically significant improvement in outcome in patients with ER-negative inflammatory breast cancer." 10/01/2001 - "Paclitaxel in the multimodality treatment for inflammatory breast carcinoma." 02/01/1997 - "High-dose single-agent paclitaxel is currently being explored in the management of inflammatory breast cancer and as part of neoadjuvant chemotherapy for stages II and III operable disease." 11/01/2013 - "We conclude that the combination therapy of bevacizumab plus paclitaxel is a useful treatment for inflammatory breast cancer. " 07/10/2010 - "Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."
3.	Epirubicin (Ellence)FDA LinkGeneric 12/01/2006 - "Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial." 03/01/2003 - "Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?" 07/01/1991 - "[A case of inflammatory breast cancer successfully treated with intra-arterial infusion of high-dose epirubicin]." 07/01/1991 - "A 56-year-old female with extensive inflammatory breast cancer was treated with intra-arterial infusion chemotherapy using a high dose of epirubicin. " 07/01/2012 - "We evaluated the efficacy and safety of the epirubicin plus docetaxel(ET)regimen, which is a combination of active agents given to patients with inflammatory breast cancer(IBC)as a primary therapy. "
4.	trastuzumab (Herceptin)FDA Link 05/01/2014 - "In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete response rate and event-free survival. " 02/01/2015 - "HannaH (NCT00950300) was a phase III, randomized, international, open-label study that compared pharmacokinetics (PK), efficacy, and safety of two different trastuzumab formulations [subcutaneous (s.c.) and intravenous (i.v.)] in HER2-positive, operable, locally advanced, or inflammatory breast cancer in the neoadjuvant/adjuvant setting. " 10/01/2011 - "To describe surgical outcomes in patients with HER2-positive locally advanced (LABC) or inflammatory breast cancer (IBC) participating in the NeOAdjuvant Herceptin (NOAH) study (ISRCTN86043495). " 12/01/2010 - "This is the first reported case of advanced inflammatory breast cancer with an invasive micropapillary component showing a clinically complete response to trastuzumab-containing treatment. " 10/01/2008 - "Trastuzumab in inflammatory breast cancer."
5.	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 07/01/2000 - "The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease > or =10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. " 11/01/1999 - "The purpose of this study was to determine outcomes for 56 patients with inflammatory breast cancer (IBC) receiving high-dose chemotherapy (HDC) with cyclophosphamide, thiotepa and carboplatin (CTCb) with peripheral blood stem cell (PBSC) support. " 01/01/1993 - "The Dana-Farber Cancer Institute/Beth Israel Hospitals have developed the high-dose intensification regimen of cyclophosphamide, thiotepa, and carboplatin (CTCb) for use in women with metastatic and high-risk stage IIIB/inflammatory breast cancer. " 01/01/1994 - "Women were treated on one of six protocols: four sequential phase II protocols for metastatic breast cancer involving cyclophosphamide at a dose of 6000 mg/m2, thiotepa at 500 mg/m2, and carboplatin at 800 mg/m2 (CTCb) chemotherapy; one phase II study of CTCb chemotherapy for stage III or inflammatory breast cancer; and a Cancer and Leukemia Group B phase III study of cyclophosphamide, carmustine, and cisplatin for women with more than 10 involved lymph nodes after primary therapy. " 01/01/1986 - "In the present study 145 patients, including 67 with inflammatory breast cancer (IBC), were treated with 4-6 weeks of Velbe, thiotepa, methotrexate, fluorouracil and prednisone, with Adriblastin added for patients with IBC, T greater than 7 cm, or N2, N3. "
6.	Cisplatin (Platino)FDA LinkGeneric 09/01/1987 - "[A case report of inflammatory breast cancer effectively treated with cis-platinum]." 09/01/2008 - "A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy. " 08/01/1996 - "Clinically, inflammatory breast cancer was suspected, and right mastectomy with ipsilateral axillary lymph node dissection was performed after intraarterial infusion chemotherapy using a cis-platinum derivative. " 05/01/2007 - "A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer." 09/01/2005 - "A genotype association study was conducted on 85 chemotherapy-naïve patients with metastatic or inflammatory breast cancer that were evaluated for an extended period after receiving standard-dose chemotherapy followed by high-dose cyclophosphamide, cisplatin, and carmustine. "
7.	bevacizumab FDA Link 04/01/2012 - "Further confirmation of use of bevacizumab in inflammatory breast cancer is needed. " 09/01/2007 - "Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience." 07/01/2014 - "Additionally, 3 patients with pleural effusion and 2 with inflammatory breast cancer received bevacizumab. " 11/01/2013 - "We conclude that the combination therapy of bevacizumab plus paclitaxel is a useful treatment for inflammatory breast cancer. " 03/15/2015 - "The BEVERLY-2 single-arm phase II trial assessed the efficacy and safety of combining neoadjuvant chemotherapy with bevacizumab and trastuzumab for the treatment of HER2-positive inflammatory breast cancer (IBC). "
8.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/01/2000 - "This study was designed to investigate the quality of life (QOL) of patients enrolled onto the High-Dose Chemotherapy for Breast Cancer Study Group trial (PEGASE 02), a French pilot multicenter trial of the treatment of inflammatory breast cancer (IBC) aimed at evaluating (1) toxicity and feasibility of sequential high-dose chemotherapy (HDC) with recombinant human granulocyte colony-stimulating factor (filgrastim) and stem-cell support and (2) response to HDC in terms of pathologic response and survival. " 04/01/2001 - "A total of 47 G-CSF mobilized stem cell grafts from patients with nodal-positive (n = 30), chemosensitive metastatic (n = 11), and 5 women with inflammatory breast cancer were evaluated for cancer cells by immunocytochemistry. " 03/10/2011 - "Patients with inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to 21-day doxorubicin and cyclophosphamide administered for five cycles (standard arm) versus weekly doxorubicin and daily oral cyclophosphamide administered with granulocyte colony-stimulating factor support for 15 weeks (continuous arm). " 07/01/1995 - "To compare the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) versus its inert vehicle in patients with unilateral nonmetastatic inflammatory breast cancer treated with fluorouracil, epirubicin, and cyclophosphamide high-dose (FEC-HD) neoadjuvant chemotherapy. " 01/01/1999 - "The aim of the study was to investigate a dose-intensified, preoperative chemotherapy with 3 cycles (cy) of epirubicin 60 mg/m2, ifosfamide 5 g/m2 with mesna 5 g/m2, biweekly with G-CSF 5 micrograms/kg (filgrastim), in terms of toxicity, clinical and pathological remission rates and changes of immunohistochemical characteristics (ER, PR, c-erbB2, p53) during chemotherapy of inoperable patients (pt) with poor prognosis (locally advanced (LABC, 9 pt), inflammatory breast cancer (IBC, 12 pt) and M0. "
9.	Filgrastim (Neupogen)FDA Link 02/01/2000 - "This study was designed to investigate the quality of life (QOL) of patients enrolled onto the High-Dose Chemotherapy for Breast Cancer Study Group trial (PEGASE 02), a French pilot multicenter trial of the treatment of inflammatory breast cancer (IBC) aimed at evaluating (1) toxicity and feasibility of sequential high-dose chemotherapy (HDC) with recombinant human granulocyte colony-stimulating factor (filgrastim) and stem-cell support and (2) response to HDC in terms of pathologic response and survival. " 01/01/1999 - "The aim of the study was to investigate a dose-intensified, preoperative chemotherapy with 3 cycles (cy) of epirubicin 60 mg/m2, ifosfamide 5 g/m2 with mesna 5 g/m2, biweekly with G-CSF 5 micrograms/kg (filgrastim), in terms of toxicity, clinical and pathological remission rates and changes of immunohistochemical characteristics (ER, PR, c-erbB2, p53) during chemotherapy of inoperable patients (pt) with poor prognosis (locally advanced (LABC, 9 pt), inflammatory breast cancer (IBC, 12 pt) and M0. " 04/20/2006 - "Forty-eight patients with immunohistochemistry-confirmed HER2-positive LABC or inflammatory breast cancer received 12 weeks of docetaxel, cisplatin, and trastuzumab with filgrastim, followed by surgery, adjuvant doxorubicin and cyclophosphamide, and locoregional radiotherapy with or without tamoxifen. "
10.	Melphalan (Alkeran)FDA LinkGeneric 07/01/2000 - "The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease > or =10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. " 08/01/2012 - "In this study, patients initiated high-dose chemotherapy with STAMP-V (carboplatin, thiotepa, and cyclophosphamide), ACT (doxorubicin, paclitaxel, and cyclophosphamide), or tandem melphalan and STAMP-V. Eighty-six patients were diagnosed with locally advanced/inflammatory (17 inflammatory) breast cancer, and 12 were diagnosed with oligometastatic breast cancer. " 09/01/1990 - "Pulmonary function tests (standard vital capacity, SVC; total lung capacity, TLC; forced expiratory volume in 1 second-forced vital capacity ratio, FEV1/FVC; carbon monoxide transfer factor, DLCO) were prospectively evaluated in patients (median age 25 years, 13-52 years; median follow-up 20 months, 6-51 months) with Hodgkin's disease (15 patients), non-Hodgkin's lymphoma (9 patients), and inflammatory breast cancer (3 patients) treated with sequential high-dose therapy comprising the following phases over approximately 2 months: a) cyclophosphamide (7 g/m2); b) vincristine (1.4 mg/m2), methotrexate (8 g/m2), and cisplatinum (120 mg/m2) or etoposide (2 g/m2); c) total body irradiation (TBI; 12.5 gy, 5 fractions over 48 hours), intravenous melphalan (120-180 mg/m2), and transplantation of autologous peripheral blood and/or bone marrow hematopoietic stem cells. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 04/15/1988 - "These results suggest that IA chemotherapy is a very useful induction therapy for inflammatory breast cancer in terms of excellent local effects and the short time required for therapy before surgery." 09/01/2011 - "In this set of patients, the clinical efficacy of the two alternative primary systemic chemotherapies (A + and TE) is equivalent in the treatment of inflammatory breast cancer (IBC), despite of the significant difference in favour of A + noticed in CRs. " 10/01/1999 - "Despite the generalization of induction chemotherapy and a better outcome for chemosensitive diseases, the prognosis of inflammatory breast cancer (IBC) is still poor. " 06/01/1992 - "A combined modality approach with chemotherapy, surgery, and radiation therapy has improved disease-free and overall survival rates for inflammatory breast cancer. " 07/01/2001 - "The purpose of this study was to evaluate the efficacy of concurrent chemotherapy and irradiation in inflammatory breast cancer (IBC). "
2.	Radiotherapy 02/01/2010 - "In a meta-analysis of five studies of non-inflammatory breast cancer without radiotherapy, local recurrence was increased by an involved or close margin (relative risk 2.6; P<0.00001). " 05/01/1990 - "The present study indicates that radiotherapy is necessary to improve local control and to increase DFS in inflammatory breast cancer. " 08/01/2015 - "Radiotherapy is an important part in the treatment of locally advanced and inflammatory breast cancer that should be given to all patients regardless to the intensity and effect of neoadjuvant systemic treatment and the extent of surgery. " 08/01/2015 - "International and national guidelines are in agreement that locally advanced, at least if regarded primarily unresectable and inflammatory breast cancer should receive neoadjuvant systemic therapy first, followed by surgery and radiotherapy. " 04/01/2013 - "Management of inflammatory breast cancer: focus on radiotherapy with an evidence-based approach."
3.	Mastectomy (Mammectomy) 11/01/2011 - "In mastectomy for inflammatory breast cancer, an immediate reconstruction with a muscle cutaneous flap enabled unhesitating mastectomy in a wide area, and thus we consider this will be a useful technique." 11/01/2011 - "[Usefulness of immediate reconstruction after mastectomy for inflammatory breast cancer with muscle cutaneous flap]." 02/01/2010 - "In two separate meta-analyses, risk of relapse was related to margin status in women with inflammatory breast cancer (relative risk 3.1; P<0.0001) but not in those undergoing skin-sparing mastectomy (relative risk 2.1; P=0.16)." 07/15/2007 - "Of these, the 106 patients without inflammatory breast cancer who were treated with mastectomy were analyzed. " 01/01/2005 - "Mastectomy alone as a treatment for inflammatory breast cancer results in local recurrence in 20% of cases and a median survival of only 2 years. "
4.	Segmental Mastectomy (Lumpectomy) 05/01/2012 - "In the 1980 s, NST was shown to substantially improve breast-conserving surgery rates and was first typically used for patients with inoperable locally advanced or inflammatory breast cancer. " 05/01/2006 - "Thirty-three non-inflammatory breast cancer patients underwent surgery, 29 with breast-conserving surgery (87.9%). " 02/01/2015 - "Five patients with a history of prior partial mastectomy and irradiation developed inflammatory breast cancer and underwent immediate reconstruction following completion mastectomy. " 04/01/1999 - "Contraindications for breast preservation are large tumors without remission after preoperative chemotherapy, multicentricity, extensive intraductal component, large ductal carcinoma in situ, inflammatory breast cancer after preoperative chemotherapy, Paget disease and local recurrence after breast-conserving surgery. " 05/01/2014 - "Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB. "
5.	Neoadjuvant Therapy 04/01/1999 - "Of the 90 patients identified with inflammatory breast cancer, 33 received neoadjuvant therapy (NEO) consisting of chemotherapy followed by surgery with radiation (n = 26) and without radiation (n = 7). " 05/01/2014 - "These results show a sustained benefit in event-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastuzumab in patients with locally advanced or inflammatory breast cancer, and provide new insight into the association between pathological complete remission and long-term outcomes in HER2-positive disease." 10/01/2011 - "Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study." 08/01/2012 - "Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer." 09/01/2009 - " panel focussed on the use of trastuzumab and other HER2-targeted agents as neoadjuvant therapy in primary operable, locally advanced, and inflammatory breast cancer; and possible choices of chemotherapeutic regimens with trastuzumab.The"